HK1197264A1 - Ion concentration-dependent binding molecule library - Google Patents

Ion concentration-dependent binding molecule library

Info

Publication number
HK1197264A1
HK1197264A1 HK14110511A HK14110511A HK1197264A1 HK 1197264 A1 HK1197264 A1 HK 1197264A1 HK 14110511 A HK14110511 A HK 14110511A HK 14110511 A HK14110511 A HK 14110511A HK 1197264 A1 HK1197264 A1 HK 1197264A1
Authority
HK
Hong Kong
Prior art keywords
binding molecule
ion concentration
dependent binding
molecule library
library
Prior art date
Application number
HK14110511A
Other languages
English (en)
Chinese (zh)
Inventor
井川智之
石井慎也
舩木美步
廣庭奈緒香
清水駿
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197264A1 publication Critical patent/HK1197264A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14110511A 2011-09-30 2014-10-21 Ion concentration-dependent binding molecule library HK1197264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218006 2011-09-30
JP2012123479 2012-05-30
PCT/JP2012/006254 WO2013046722A1 (ja) 2011-09-30 2012-09-28 イオン濃度依存性結合分子ライブラリ

Publications (1)

Publication Number Publication Date
HK1197264A1 true HK1197264A1 (en) 2015-01-09

Family

ID=47994796

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103922.7A HK1244517A1 (zh) 2011-09-30 2014-10-21 離子濃度依賴性結合分子文庫
HK14110511A HK1197264A1 (en) 2011-09-30 2014-10-21 Ion concentration-dependent binding molecule library

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103922.7A HK1244517A1 (zh) 2011-09-30 2014-10-21 離子濃度依賴性結合分子文庫

Country Status (15)

Country Link
US (3) US10024867B2 (de)
EP (2) EP3778889A1 (de)
JP (4) JP6284766B2 (de)
KR (2) KR102528622B1 (de)
CN (3) CN103975060B (de)
AU (2) AU2012313594C1 (de)
BR (2) BR122019023952B1 (de)
CA (2) CA3186007A1 (de)
HK (2) HK1244517A1 (de)
IN (1) IN2014CN03066A (de)
MX (2) MX366269B (de)
RU (1) RU2732151C2 (de)
SG (2) SG10202102283TA (de)
TW (3) TWI794658B (de)
WO (1) WO2013046722A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101479381B (zh) 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US9334334B2 (en) 2012-03-16 2016-05-10 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
DK2825037T3 (da) 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
AU2013251309B2 (en) * 2012-04-27 2017-06-22 Bioatla, Llc Modified antibody regions and uses thereof
KR20150016579A (ko) 2012-05-30 2015-02-12 추가이 세이야쿠 가부시키가이샤 표적 조직 특이적 항원 결합 분자
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
WO2015042250A1 (en) * 2013-09-18 2015-03-26 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2015175375A1 (en) * 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
US10183994B2 (en) 2014-06-30 2019-01-22 Merck Patent Gmbh Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence
JP6858559B2 (ja) * 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
ES2913865T3 (es) * 2014-08-28 2022-06-06 Bioatla Inc Receptores de antígeno quimérico condicionalmente activos para células T modificadas
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
NZ731491A (en) * 2014-10-23 2021-12-24 Kira Biotech Pty Ltd Cd83 binding proteins and uses thereof
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CA3225013A1 (en) * 2015-02-24 2016-09-01 Bioatla, Llc Conditionally active proteins
EP3302553A4 (de) * 2015-05-28 2019-03-06 Bio-rad Laboratories, Inc. Affinitätsliganden und entsprechende verfahren
TWI621628B (zh) 2015-09-18 2018-04-21 日商中外製藥股份有限公司 Ｉｌ－８結合抗體及其用途
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SI3455261T1 (sl) 2016-05-13 2023-01-31 Bioatla, Inc. Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
GB201615254D0 (en) * 2016-09-08 2016-11-23 Ge Healthcare Bio Sciences Ab Novel Ligand and use thereof
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
CA3059542A1 (en) * 2017-04-12 2018-10-18 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
US11149094B2 (en) * 2017-06-05 2021-10-19 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
WO2019064463A1 (ja) * 2017-09-28 2019-04-04 学校法人中部大学 バイオアフィニティーを利用したウイルス又は細菌の濃縮方法及び装置
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
WO2020041532A1 (en) * 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
EP3854815A4 (de) * 2018-10-10 2022-03-16 BGI Shenzhen Einkettiger anti-bcma-antikörper scfv, verfahren zu seiner herstellung und seine verwendung
WO2020186111A2 (en) * 2019-03-12 2020-09-17 xCella Biosciences, Inc. Vista-binding antibodies and uses thereof
JP2022525261A (ja) * 2019-03-12 2022-05-11 ザイエンス・セラピューティクス・インコーポレイテッド ビスタ結合抗体およびその使用
WO2021087368A2 (en) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
CN112086160B (zh) * 2020-08-26 2023-09-22 江西中医药大学 基于Softmax和混合粒子群的中药量效拟合方法
AU2022295067A1 (en) 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインｃの分離方法
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
EP0656941B1 (de) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0754225A4 (de) 1993-04-26 2001-01-31 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US6214613B1 (en) * 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
EP0731842A1 (de) 1993-12-03 1996-09-18 Medical Research Council Rekombinante indungsproteine und -peptide
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
EP1978033A3 (de) 1995-04-27 2008-12-24 Amgen Fremont Inc. Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2141243A3 (de) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Proteingerüste für Antikörpermimetika und andere Bindungsproteine
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
DE10207178A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Komponenten für die Herstellung amphoterer Liposomen
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP2049564B1 (de) 2006-08-02 2017-05-17 The UAB Research Foundation Verfahren und zusammensetzungen in zusammenhang mit löslichen monoklonalen viariablen lymphozytrezeptoren mit bestimmter antigenspezifität
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
ES2394471T3 (es) 2007-09-28 2013-02-01 Chugai Seiyaku Kabushiki Kaisha Anticuerpo Anti-Glipicano 3 que tiene una cinética mejorada en plasma
US8728982B2 (en) 2007-12-19 2014-05-20 Centoco Ortho Biotech Inc. Engineered hybrid phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage
DK2235059T3 (en) 2007-12-26 2015-03-30 Xencor Inc FC-VERSIONS OF MODIFIED BINDING TO FcRn
CN103251948A (zh) * 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
SG196839A1 (en) * 2008-04-25 2014-02-13 Dyax Corp Antibodies against fcrn and use thereof
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
WO2010058860A1 (ja) * 2008-11-18 2010-05-27 株式会社シノテスト 試料中のｃ反応性蛋白質の測定方法及び測定試薬
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
JP2011184418A (ja) * 2010-03-11 2011-09-22 Tokyo Institute Of Technology 親和性可変抗体
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
CN107973851A (zh) * 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子

Also Published As

Publication number Publication date
JP2022028652A (ja) 2022-02-16
IN2014CN03066A (de) 2015-08-07
BR112014007353A2 (pt) 2017-04-04
JP7012044B2 (ja) 2022-02-10
JP7313410B2 (ja) 2023-07-24
RU2014117636A (ru) 2015-11-10
BR122019023952B1 (pt) 2022-09-20
TWI710675B (zh) 2020-11-21
JPWO2013046722A1 (ja) 2015-03-26
US20220187308A1 (en) 2022-06-16
CN103975060A (zh) 2014-08-06
KR102276528B1 (ko) 2021-07-12
TWI794658B (zh) 2023-03-01
US10024867B2 (en) 2018-07-17
US20190041396A1 (en) 2019-02-07
KR20140069074A (ko) 2014-06-09
WO2013046722A1 (ja) 2013-04-04
EP3778889A1 (de) 2021-02-17
KR102528622B1 (ko) 2023-05-04
EP2762564A4 (de) 2015-04-29
JP6523387B2 (ja) 2019-05-29
AU2018201987A1 (en) 2018-04-12
JP6284766B2 (ja) 2018-02-28
MX2019007958A (es) 2019-08-29
CA3186007A1 (en) 2013-04-04
KR20210091341A (ko) 2021-07-21
CN103975060B (zh) 2021-04-13
US20140271617A1 (en) 2014-09-18
TW201738417A (zh) 2017-11-01
RU2732151C2 (ru) 2020-09-11
AU2012313594A1 (en) 2014-04-17
AU2018201987B2 (en) 2020-10-01
EP2762564A1 (de) 2014-08-06
EP2762564B1 (de) 2020-09-16
BR112014007353B1 (pt) 2022-09-13
CA2850041C (en) 2023-03-14
US11243210B2 (en) 2022-02-08
JP2018070589A (ja) 2018-05-10
CN113061993A (zh) 2021-07-02
MX366269B (es) 2019-07-04
CN107287660A (zh) 2017-10-24
JP2019193629A (ja) 2019-11-07
AU2012313594C1 (en) 2018-05-10
TW201329299A (zh) 2013-07-16
TW202106936A (zh) 2021-02-16
SG10202102283TA (en) 2021-04-29
MX2014003662A (es) 2014-04-30
AU2012313594B2 (en) 2018-02-01
HK1244517A1 (zh) 2018-08-10
SG11201401102VA (en) 2014-09-26
CA2850041A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
HK1197264A1 (en) Ion concentration-dependent binding molecule library
IL270223B (en) Molecules that specifically bind tdp–43
HK1198630A1 (en) Protein carrier-linked prodrugs
HK1214938A1 (zh) 分析輔件
GB201104542D0 (en) Content provision
EP2685487A4 (de) Massenspektrometer
AU341416S (en) Dehumidifier housing
EP2754036A4 (de) Szenariobasierte animationsbibliothek
GB2493276B (en) RF ion guides
EP2766917A4 (de) Massenspektrometer
PL3617697T3 (pl) Zsynchronizowana modyfikacja jonów
IL235134A0 (en) il–6 binding molecules
EP2720722A4 (de) Molekül mit mehreren vinylsulfonen
GB201117158D0 (en) Ion guide
EP2739764A4 (de) Ionenquelle
EP2779208A4 (de) Massenspektrometer
EP2671947A4 (de) Peptidbibliothek
EP2770523A4 (de) Massenspektrometer
EP2732447A4 (de) Hörprobe
EP2793918A4 (de) Hdc-sign-bindende peptide
EP2793021A4 (de) Proteinadsorbens
IL227971A0 (en) Substances that inhibit the transport of glycine
GB201200563D0 (en) Binding molecule
GB201116477D0 (en) Modified boot
GB201113890D0 (en) Binding surfaces